MARKET

ARDS

ARDS

Aridis Pharmaceuticals
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.50
+0.09
+1.44%
Closed 16:00 07/10 EDT
OPEN
6.50
PREV CLOSE
6.41
HIGH
6.95
LOW
6.23
VOLUME
9.28K
TURNOVER
--
52 WEEK HIGH
12.40
52 WEEK LOW
3.800
MARKET CAP
58.00M
P/E (TTM)
-1.9883
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ARDS stock price target is 18.60 with a high estimate of 25.00 and a low estimate of 11.00.

EPS

ARDS News

More
Aridis Pharmaceuticals to Participate in Cantor Fitzgerald Virtual Symposium: Winning Ways to Treat Infections and COVID-19
PR Newswire · 06/26 10:30
8 Stock Catalysts For The Week Ahead
The SPDR S&P 500 (NYSE: SPY) started off the week on a high note on Monday morning after a turbulent week of trading last week. Here are eight potential catalysts coming this week that could move the markets.
Benzinga · 06/22 15:30
Aridis's AR-501 shows positive effect in early-stage study
Seeking Alpha - Article · 06/22 15:17
Aridis Reports Positive Safety Data in Healthy Subjects of a Phase 1/2a Clinical Trial of AR-501
Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) announced today positive results from the Phase 1 portion of its Phase 1/2a clinical trial of AR-501, an inhaled formulation of gallium citrate being developed for the treatment of chronic lung infections in patients
Benzinga · 06/22 10:20
Aridis Reports AR-501 Clinical Data: Positive Safety Data in Healthy Subjects of a Phase 1/2a Clinical Trial
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today positive results from the Phase 1 portion of its Phase 1/2
PR Newswire · 06/22 09:30
The Week Ahead In Biotech: Karyopharm, Zogenix, Heron, Chiasma On The Radar Ahead Of FDA Decisions
Biotech stocks rebounded along with the broader market in the week ended June 19.
Benzinga · 06/21 18:53
Aridis Pharmaceuticals to Discuss APEX in Virtual Fireside Chat Hosted by Cantor Fitzgerald on June 25th
PR Newswire · 06/18 10:30
Aridis Pharmaceuticals Appoints Dr. Hasan Jafri as Chief Medical Officer
PR Newswire · 06/15 10:30

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About ARDS

Aridis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs), to treat infections. mAbs represents treatment approach that enables the human immune system to fight infections and are designed to overcome the deficiencies associated with current therapies, such as rise in drug resistance, short duration of response, negative impact on the human microbiome, and lack of differentiation among the treatment alternatives. Its product pipeline comprises of human mAbs targeting specific pathogens associated with bacterial infections, primarily hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). Its lead product candidate, AR-301 targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus, a common pathogen associated with HAP and VAP. Its AR-101 (Aerumab) is a fully human immunoglobulin M, mAb targeting P. aeruginosa serotype O11.
More

Webull offers kinds of Aridis Pharmaceuticals Inc stock information, including NASDAQ:ARDS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARDS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARDS stock methods without spending real money on the virtual paper trading platform.